Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...
Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.
A new gold-based drug can slow tumor growth in animals by 82% and target cancers more selectively than standard chemotherapy drugs, according to a study by Australian and Indian researchers. The RMIT ...
The rise of AMR in pathogenic bacteria poses serious challenges to the control and management of infectious diseases. Globally, the rise of antimicrobial ...
Isomorphic Labs, the London-based, drug discovery–focused spinout of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli ...
In developing drugs using a platform that joins physics with machine learning, Schrödinger sees more than a passing resemblance to the studio whose Toy Story and other computer-generated movies ...
TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...
This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback